Clinical Trial

Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the impact of pre-operative cryoablation, and immune checkpoint inhibition (ICI) on on 3-year Event Free Survival (EFS), in women with residual hormone receptor negative, HER2-negative ("triple negative") resectable breast cancer after taxane-based neoadjuvant chemotherapy.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-06 -> 2027-06 2026-07-23
minor Completion pushed: 2028-06 -> 2029-06 2026-07-23
Trial Details
NCT Number NCT03546686
Lead Sponsor University of Texas Southwestern Medical Center
Collaborators: Susan G. Komen Breast Cancer Foundation, Bristol-Myers Squibb, Boston Scientific Corporation, American Society of Clinical Oncology
Conditions Breast Cancer
Enrollment 51 participants
Start Date 2019-11-12
Primary Completion 2027-06 (estimated)
Study Completion 2029-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-22